Post-IPO Equity - SAGE Therapeutics
Investment Firm
Overview
SAGE Therapeutics develops and delivers novel medicines for most debilitating and disabling central nervous system disorders.
Announced Date
Nov 27, 2020
Funding Type
Post Ipo Equity
Highlights
Location
United States, North America
Social
Participant Investors
1
| Investor Name |
|---|
 Biogen |
Round Details and Background
SAGE Therapeutics raised $650000000 on 2020-11-27 in Post-IPO Equity
SAGE Therapeutics develops and delivers novel medicines for most debilitating and disabling central nervous system disorders.
Company Funding History
10
| Announcment Date | Transaction Name | Number Of Investors | Lead Investor | Money Raised |
|---|---|---|---|---|
| Apr 13, 2015 |  Post-IPO Equity - SAGE Therapeutics | - | 138.0M | |
| Mar 13, 2014 | Series C - SAGE Therapeutics | 5 | - | 38.0M |
| Oct 16, 2013 | Series B - SAGE Therapeutics | 2 | - | 20.0M |
| Oct 18, 2011 | Series A - SAGE Therapeutics | 1 | - | 35.0M |
Recent Activity
There is no recent news or activity for this profile.